Lead Discovery Center GmbH and Qli5 Therapeutics GmbH have described macrocyclic compounds acting as proteasome subunit β type-5 (PSMB5) inhibitors reported to be useful for the treatment of cancer, infections, inflammatory disorders, myasthenia gravis and transplant rejection.
Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged pranoprofen derivatives reported to be useful for the treatment of pain and eye disorders.
Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently linked to an MDM2 targeting moiety through a linker and reported to be useful for the treatment of cancer.
Therabest Co. Ltd. has identified glutathione (GSH) or hydrogen peroxide (H2O2)-activated prodrugs comprising obeticholic acid dimers conjugated via linkers and their nanogels coated with fucoidan reported to be useful for the treatment of liver diseases.
Xenon Pharmaceuticals Inc. has synthesized pyridinyl derivatives acting as sodium channel protein type 1 subunit α (SCN1A; Nav1.1) activators reported to be useful for the treatment of epilepsy.
RSS